Patents by Inventor Aaron D. Gitler

Aaron D. Gitler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLOE1-MEDIATED MODULATION OF SEED LONGEVITY AND GERMINATION RATES
    Publication number: 20230416772
    Abstract: Described herein are methods of modulating seed germination and seed longevity in plants by modifying FLOE1 level or activity; and plants generated by such methods.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 28, 2023
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Carnegie Institution of Washington
    Inventors: Yanniv Dorone, Steven Boeynaems, Aaron D. Gitler, Seung Yon Rhee
  • Modulators of alpha-synuclein toxicity
    Patent number: 10526651
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER to Golgi trafficking. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 7, 2020
    Assignees: Whitehead Institute for Biomedical Research, The Curators of the University of Missouri
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes
  • Yeast cells expressing TAR DNA-binding protein 43 and uses therefor
    Patent number: 10428335
    Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: October 1, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • YEAST CELLS EXPRESSING TAR DNA-BINDING PROTEIN 43 AND USES THEREFOR
    Publication number: 20190010507
    Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 10, 2019
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Yeast cells expressing TAR DNA-binding protein 43 and uses therefor
    Patent number: 10106803
    Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: October 23, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Modulators of alpha-synuclein toxicity
    Patent number: 9909160
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 6, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Modulators of alpha-synuclein toxicity
    Patent number: 9879257
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: January 30, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • YEAST CELLS EXPRESSING TAR DNA-BINDING PROTEIN 43 AND USES THEREFOR
    Publication number: 20170321222
    Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 9, 2017
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Yeast cells expressing TAR DNA-binding protein 43 and uses therefor
    Patent number: 9738898
    Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: August 22, 2017
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20160215321
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: December 21, 2015
    Publication date: July 28, 2016
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20160046933
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: March 24, 2015
    Publication date: February 18, 2016
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • Modulators of alpha-synuclein toxicity
    Patent number: 9249444
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: February 2, 2016
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Novel Gene Targets Associated with Amyotrophic Lateral Sclerosis and Methods of Use Thereof
    Publication number: 20150252424
    Abstract: Novel gene targets and methods of use thereof for the diagnosis and treatment of Amyotrophic Lateral Sclerosis are provided.
    Type: Application
    Filed: March 3, 2015
    Publication date: September 10, 2015
    Inventor: Aaron D. Gitler
  • Modulators of alpha-synuclein toxicity
    Patent number: 9018003
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: April 28, 2015
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • Gene targets associated with amyotrophic lateral sclerosis and methods of use thereof
    Patent number: 8969005
    Abstract: Compositions and methods for diagnosis and treatment of ALS are provided.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 3, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Aaron D. Gitler
  • Methods of identifying modulators of TDP-43 mediated cellular toxicity
    Patent number: 8865411
    Abstract: Compositions and methods are disclosed for identifying agents useful for the treatment of proteinopathies.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: October 21, 2014
    Assignees: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: Aaron D. Gitler, Andrew Elden
  • MODULATORS OF ALPHA-SYNUCLEIN TOXICITY
    Publication number: 20140051091
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Application
    Filed: June 28, 2013
    Publication date: February 20, 2014
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Modulators of alpha-synuclein toxicity
    Patent number: 8501465
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: August 6, 2013
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler
  • Modulators of alpha-synuclein toxicity
    Patent number: 8399241
    Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: March 19, 2013
    Assignees: Whitehead Institute for Biomedical Research, The Curators of the University of Missouri
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar, Antony A. Cooper, Cole M. Haynes
  • Novel Gene Targets Associated with Amyotrophic Lateral Sclerosis and Methods of Use Thereof
    Publication number: 20130059757
    Abstract: Compositions and methods for diagnosis and treatment of ALS are provided.
    Type: Application
    Filed: March 28, 2011
    Publication date: March 7, 2013
    Applicant: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Aaron D. Gitler